Which has stronger valuation & earnings, CDNA or ABVX?

CareDx has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CareDx $379.80M 6.78 -$21.35M $2.07 24.05 Abivax N/A N/A -$380.27M -$5.21 N/A

Is CDNA or ABVX more profitable?

CareDx has a net margin of 24.23% compared to Abivax's net margin of 0.00%. CareDx's return on equity of 2.87% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets CareDx 24.23% 2.87% 2.17% Abivax N/A -99.02% -70.26%

Does the media prefer CDNA or ABVX?

In the previous week, CareDx had 10 more articles in the media than Abivax. MarketBeat recorded 14 mentions for CareDx and 4 mentions for Abivax. CareDx's average media sentiment score of 1.29 beat Abivax's score of 1.24 indicating that CareDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTGX or CDNA?

In the previous week, Protagonist Therapeutics had 8 more articles in the media than CareDx. MarketBeat recorded 22 mentions for Protagonist Therapeutics and 14 mentions for CareDx. Protagonist Therapeutics' average media sentiment score of 1.45 beat CareDx's score of 1.29 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 18 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, KYMR or CDNA?

CareDx has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 250.55 -$311.35M -$3.24 N/A CareDx $379.80M 6.78 -$21.35M $2.07 24.05

Does the media favor KYMR or CDNA?

In the previous week, Kymera Therapeutics had 4 more articles in the media than CareDx. MarketBeat recorded 18 mentions for Kymera Therapeutics and 14 mentions for CareDx. Kymera Therapeutics' average media sentiment score of 1.65 beat CareDx's score of 1.29 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CareDx 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CDNA or IONS?

In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than CareDx. MarketBeat recorded 23 mentions for Ionis Pharmaceuticals and 14 mentions for CareDx. Ionis Pharmaceuticals' average media sentiment score of 1.50 beat CareDx's score of 1.29 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 20 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, CYTK or CDNA?

CareDx has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $88.04M 101.89 -$784.96M -$7.22 N/A CareDx $379.80M 6.78 -$21.35M $2.07 24.05

Is CYTK or CDNA more profitable?

CareDx has a net margin of 24.23% compared to Cytokinetics' net margin of -1,321.12%. CareDx's return on equity of 2.87% beat Cytokinetics' return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -1,321.12% N/A -51.01% CareDx 24.23% 2.87% 2.17%

Does the media refer more to CYTK or CDNA?

In the previous week, Cytokinetics had 3 more articles in the media than CareDx. MarketBeat recorded 17 mentions for Cytokinetics and 14 mentions for CareDx. CareDx's average media sentiment score of 1.29 beat Cytokinetics' score of 0.82 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CareDx (CDNA) Competitors

$49.79 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

CDNA vs. ABVX, PTGX, KYMR, IONS, and CYTK

Should you buy CareDx stock or one of its competitors? CareDx's main competitors and comparable companies include Abivax (ABVX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), Ionis Pharmaceuticals (IONS), and Cytokinetics (CYTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CareDx compare to Abivax?

CareDx (NASDAQ:CDNA) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

CareDx has a net margin of 24.23% compared to Abivax's net margin of 0.00%. CareDx's return on equity of 2.87% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Abivax	N/A	-99.02%	-70.26%

CareDx presently has a consensus price target of $47.75, suggesting a potential downside of 4.10%. Abivax has a consensus price target of $156.50, suggesting a potential upside of 38.07%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

CareDx has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, Abivax has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

CareDx has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	6.78	-$21.35M	$2.07	24.05
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

In the previous week, CareDx had 10 more articles in the media than Abivax. MarketBeat recorded 14 mentions for CareDx and 4 mentions for Abivax. CareDx's average media sentiment score of 1.29 beat Abivax's score of 1.24 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are held by institutional investors. 2.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CareDx beats Abivax on 12 of the 16 factors compared between the two stocks.

How does CareDx compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

CareDx has higher revenue and earnings than Protagonist Therapeutics. CareDx is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	202.95	-$130.15M	$1.03	140.13
CareDx	$379.80M	6.78	-$21.35M	$2.07	24.05

Protagonist Therapeutics has a net margin of 29.40% compared to CareDx's net margin of 24.23%. Protagonist Therapeutics' return on equity of 12.03% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
CareDx	24.23%	2.87%	2.17%

Protagonist Therapeutics currently has a consensus price target of $140.53, suggesting a potential downside of 2.63%. CareDx has a consensus price target of $47.75, suggesting a potential downside of 4.10%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Protagonist Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94
CareDx	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 2.4% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Protagonist Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, CareDx has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 8 more articles in the media than CareDx. MarketBeat recorded 22 mentions for Protagonist Therapeutics and 14 mentions for CareDx. Protagonist Therapeutics' average media sentiment score of 1.45 beat CareDx's score of 1.29 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	18 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats CareDx on 12 of the 16 factors compared between the two stocks.

How does CareDx compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

In the previous week, Kymera Therapeutics had 4 more articles in the media than CareDx. MarketBeat recorded 18 mentions for Kymera Therapeutics and 14 mentions for CareDx. Kymera Therapeutics' average media sentiment score of 1.65 beat CareDx's score of 1.29 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CareDx	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	250.55	-$311.35M	-$3.24	N/A
CareDx	$379.80M	6.78	-$21.35M	$2.07	24.05

Kymera Therapeutics presently has a consensus target price of $127.17, suggesting a potential upside of 7.64%. CareDx has a consensus target price of $47.75, suggesting a potential downside of 4.10%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kymera Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.88
CareDx	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

CareDx has a net margin of 24.23% compared to Kymera Therapeutics' net margin of -285.33%. CareDx's return on equity of 2.87% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
CareDx	24.23%	2.87%	2.17%

Kymera Therapeutics has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, CareDx has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market.

Summary

CareDx beats Kymera Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CareDx compare to Ionis Pharmaceuticals?

CareDx (NASDAQ:CDNA) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

CareDx has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

CareDx has a net margin of 24.23% compared to Ionis Pharmaceuticals' net margin of -64.76%. CareDx's return on equity of 2.87% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

CareDx presently has a consensus price target of $47.75, indicating a potential downside of 4.10%. Ionis Pharmaceuticals has a consensus price target of $94.15, indicating a potential upside of 54.22%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

CareDx has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	6.78	-$21.35M	$2.07	24.05
Ionis Pharmaceuticals	$944M	10.75	-$381.39M	-$3.46	N/A

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.4% of CareDx shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than CareDx. MarketBeat recorded 23 mentions for Ionis Pharmaceuticals and 14 mentions for CareDx. Ionis Pharmaceuticals' average media sentiment score of 1.50 beat CareDx's score of 1.29 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	20 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CareDx beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does CareDx compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

CareDx has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	101.89	-$784.96M	-$7.22	N/A
CareDx	$379.80M	6.78	-$21.35M	$2.07	24.05

Cytokinetics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, CareDx has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

In the previous week, Cytokinetics had 3 more articles in the media than CareDx. MarketBeat recorded 17 mentions for Cytokinetics and 14 mentions for CareDx. CareDx's average media sentiment score of 1.29 beat Cytokinetics' score of 0.82 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics presently has a consensus target price of $102.20, indicating a potential upside of 41.77%. CareDx has a consensus target price of $47.75, indicating a potential downside of 4.10%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86
CareDx	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

CareDx has a net margin of 24.23% compared to Cytokinetics' net margin of -1,321.12%. CareDx's return on equity of 2.87% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
CareDx	24.23%	2.87%	2.17%

Summary

CareDx beats Cytokinetics on 10 of the 15 factors compared between the two stocks.

Get CareDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDNA vs. The Competition

Export

Metric	CareDx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.58B	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	24.05	11.62	273.16	25.42
Price / Sales	6.78	1,392.08	635.16	104.14
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	8.45	16.92	11.08	6.36
Net Income	-$21.35M	-$22.74M	$3.48B	$349.79M
7 Day Performance	4.82%	-0.13%	0.38%	-0.40%
1 Month Performance	13.91%	11.45%	7.89%	4.24%
1 Year Performance	264.49%	55.66%	24.71%	15.13%

CareDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDNA CareDx	3.3213 of 5 stars	$49.79 flat	$47.75 -4.1%	+264.5%	$2.58B	$379.80M	24.05	740	News Coverage Positive News
ABVX Abivax	2.4961 of 5 stars	$116.15 +1.0%	$156.50 +34.7%	+39.9%	$10.03B	N/A	N/A	61	Positive News
PTGX Protagonist Therapeutics	1.5846 of 5 stars	$154.72 +0.3%	$140.53 -9.2%	+144.4%	$9.99B	$46.02M	150.22	120	Positive News Gap Up
KYMR Kymera Therapeutics	1.6397 of 5 stars	$121.05 +1.0%	$125.65 +3.8%	+186.8%	$9.96B	$39.21M	N/A	170	Positive News
IONS Ionis Pharmaceuticals	3.8137 of 5 stars	$62.04 +3.9%	$94.15 +51.8%	+43.2%	$9.93B	$944M	N/A	1,402	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDNA) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CareDx (CDNA) Competitors

CDNA vs. ABVX, PTGX, KYMR, IONS, and CYTK

How does CareDx compare to Abivax?

Summary

How does CareDx compare to Protagonist Therapeutics?

Summary

How does CareDx compare to Kymera Therapeutics?

Summary

How does CareDx compare to Ionis Pharmaceuticals?

Summary

How does CareDx compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA vs. The Competition

CareDx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CareDx (CDNA) Competitors

CDNA vs. ABVX, PTGX, KYMR, IONS, and CYTK

How does CareDx compare to Abivax?

Is CDNA or ABVX more profitable?

Do analysts rate CDNA or ABVX?

Which has more volatility & risk, CDNA or ABVX?

Which has stronger valuation & earnings, CDNA or ABVX?

Does the media prefer CDNA or ABVX?

Do institutionals & insiders hold more shares of CDNA or ABVX?

Summary

How does CareDx compare to Protagonist Therapeutics?

Which has stronger earnings & valuation, PTGX or CDNA?

Is PTGX or CDNA more profitable?

Do analysts recommend PTGX or CDNA?

Do insiders and institutionals believe in PTGX or CDNA?

Which has more risk & volatility, PTGX or CDNA?

Does the media refer more to PTGX or CDNA?

Summary

How does CareDx compare to Kymera Therapeutics?

Does the media favor KYMR or CDNA?

Which has better valuation & earnings, KYMR or CDNA?

Do analysts recommend KYMR or CDNA?

Is KYMR or CDNA more profitable?

Which has more risk & volatility, KYMR or CDNA?

Summary

How does CareDx compare to Ionis Pharmaceuticals?

Which has more risk & volatility, CDNA or IONS?

Is CDNA or IONS more profitable?

Do analysts prefer CDNA or IONS?

Which has preferable valuation & earnings, CDNA or IONS?

Do institutionals and insiders believe in CDNA or IONS?

Does the media prefer CDNA or IONS?

Summary

How does CareDx compare to Cytokinetics?

Which has higher earnings and valuation, CYTK or CDNA?

Which has more risk and volatility, CYTK or CDNA?

Does the media refer more to CYTK or CDNA?

Do analysts rate CYTK or CDNA?

Is CYTK or CDNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA vs. The Competition

CareDx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools